The Food and Drugs Authority (FDA) and the National Medicine Regulatory Agency (NMRA) have given approval for the use of herbal medicine in a clinical trial for the treatment of coronavirus.
The use of Cryptolepsis sanguinolenta, locally known as Nibima, in the clinical trials follows results from laboratory studies conducted by the Kwame Nkrumah University of Science and Technology (KNUST) research team which points in the direction of possible clinical benefits.
The approval by the FDA forms part of the Authority’s search for treatment of the virus.
Read below details of FDA’s press statement approving the clinical trials:
Source: norvanreports
